Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Market Cap	$673.04M	P/E Ratio	N/A
52W High	$14.80	52W Low	$2.68
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	61.9%
Overall Score	54	Value Score	60
Quality Score	23	Technical Score	81

EPS Current Est	$-3.59	EPS Next Est	$-2.42
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REPL	$10.18	+3.14%	1.31M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REPL	$10.18	+3.1%	1.31M
3
4
5
6

REPL

REPL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Replimune Group Inc. Data in Excel

Get Replimune Group Inc. Data in Excel